MET and non-small cell lung carcinoma: For metastatic NSCLC patients (stage IV), targeted therapy is typically used for patients whose tumors carry driver gene mutations (e.g., EGFR, ALK, MET, ROS1, KRAS) but they are only present in a small proportion of NSCLC patients (around 25%) [10,14,15].